A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry

Alice Jane Owen; Jean Marie Spinks; Adam David Meehan; T Robb; Melissa Hardy; D Kwasha; John H Wlodarczyk; Christopher Michael Reid

doi:10.3111/13696990802034525

A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry

Alice Jane Owen, Jean Marie Spinks, Adam David Meehan, T Robb, Melissa Hardy, D Kwasha, John H Wlodarczyk, Christopher Michael Reid

Research output: Contribution to journal › Article › Research › peer-review

23 Citations (Scopus)

Original language	English
Pages (from-to)	235 - 243
Number of pages	9
Journal	Journal of Medical Economics
Volume	11
Issue number	2
DOIs	https://doi.org/10.3111/13696990802034525
Publication status	Published - 2008

Access to Document

10.3111/13696990802034525

Cite this

Owen, A. J., Spinks, J. M., Meehan, A. D., Robb, T., Hardy, M., Kwasha, D., Wlodarczyk, J. H., & Reid, C. M. (2008). A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. Journal of Medical Economics, 11(2), 235 - 243. https://doi.org/10.3111/13696990802034525

@article{92b14ec181db42478107909b1312ee2d,

title = "A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry",

author = "Owen, {Alice Jane} and Spinks, {Jean Marie} and Meehan, {Adam David} and T Robb and Melissa Hardy and D Kwasha and Wlodarczyk, {John H} and Reid, {Christopher Michael}",

year = "2008",

doi = "10.3111/13696990802034525",

language = "English",

volume = "11",

pages = "235 -- 243",

journal = "Journal of Medical Economics",

issn = "1369-6998",

publisher = "Taylor & Francis",

number = "2",

}

Owen, AJ, Spinks, JM, Meehan, AD, Robb, T, Hardy, M, Kwasha, D, Wlodarczyk, JH & Reid, CM 2008, 'A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry', Journal of Medical Economics, vol. 11, no. 2, pp. 235 - 243. https://doi.org/10.3111/13696990802034525

A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. / Owen, Alice Jane; Spinks, Jean Marie; Meehan, Adam David et al.
In: Journal of Medical Economics, Vol. 11, No. 2, 2008, p. 235 - 243.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry

AU - Owen, Alice Jane

AU - Spinks, Jean Marie

AU - Meehan, Adam David

AU - Robb, T

AU - Hardy, Melissa

AU - Kwasha, D

AU - Wlodarczyk, John H

AU - Reid, Christopher Michael

PY - 2008

Y1 - 2008

UR - http://www.informapharmascience.com/doi/abs/10.3111/13696990802034525

U2 - 10.3111/13696990802034525

DO - 10.3111/13696990802034525

M3 - Article

SN - 1369-6998

VL - 11

SP - 235

EP - 243

JO - Journal of Medical Economics

JF - Journal of Medical Economics

IS - 2

ER -

A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry

Access to Document

Other files and links

Cite this